Filtered By:
Vaccination: Meningitis Vaccine
Countries: Canada Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 82 results found since Jan 2013.
Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada
The objective was to estimate PCV13 effectiveness to prevent serotype 3 invasive pneumococcal disease in children aged less than 5 years, using 2010-2018 mandatory notification and laboratory surveillance data, an indirect cohort design and multivariate logistic regression models. A total of 29 cases of serotype 3 and 290 non-vaccine serotype cases as controls were analysed. Overall vaccine effectiveness (≥1 dose) was estimated at 59% [-39% to 88%]. During the first year after the last dose effectivness was 88% [47% to 97%] whereas no protection was observed thereafter. There was no trend towards increased effectiveness ...
Source: Vaccine - July 31, 2023 Category: Allergy & Immunology Authors: Genevi ève Deceuninck Nicholas Brousseau Brigitte Lefebvre Caroline Quach Bruce Tapiero Yen-Giang Bui Micha ël Desjardins Philippe De Wals Source Type: research
Epidemiology of invasive meningococcal disease in Canada, 2012-2019
CONCLUSION: Invasive meningococcal disease is a rare but severe infection in Canada that mostly affects the very young. Serogroup B continues to account for the greatest proportion of disease. Serogroup W associated with ST-11 CC is becoming a growing contributor of disease in all age groups not protected by serogroup W-containing vaccines.PMID:37325257 | PMC:PMC10263176 | DOI:10.14745/ccdr.v48i05a06
Source: Can Commun Dis Rep - June 16, 2023 Category: Infectious Diseases Authors: Myriam Saboui Raymond Sw Tsang Robert MacTavish Amisha Agarwal Y Anita Li Marina I Salvadori Susan G Squires Source Type: research
Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study
Vaccine. 2023 Feb 14:S0264-410X(23)00130-5. doi: 10.1016/j.vaccine.2023.02.004. Online ahead of print.NO ABSTRACTPMID:36797099 | DOI:10.1016/j.vaccine.2023.02.004
Source: Vaccine - February 16, 2023 Category: Allergy & Immunology Authors: Jelena Vojicic Ana Gabriela Grajales Alejandro Cane Source Type: research
Characterization of invasive meningococcal disease case isolates in Atlantic Canada, 2014 to 2020: spatial-temporal variations of clones and predicted meningococcal B vaccine coverage
Conclusions. This study provided evidence concerning the dynamics of N. meningitidis strains causing IMD in Atlantic Canada, with both geographical and temporal differences found. MenB vaccine appeared to provide good coverage of MenB IMD, especially towards the predominant strain of ST-154.PMID:36748536 | DOI:10.1099/jmm.0.001615
Source: Journal of Medical Microbiology - February 7, 2023 Category: Microbiology Authors: Raymond S W Tsang Dennis K S Law Jianwei Zhou David Haldane Richard Garceau George Zahariadis Kristen Mead David Alexander Source Type: research
School immunization coverage in adolescents during the COVID-19 pandemic: A retrospective cohort study
CONCLUSION: There was a substantial decrease in school-based immunization coverage during the COVID-19 pandemic, and coverage has not returned to pre-pandemic levels, suggesting further catch-up is needed.PMID:36642632 | PMC:PMC9826994 | DOI:10.1016/j.vaccine.2023.01.011
Source: Vaccine - January 15, 2023 Category: Allergy & Immunology Authors: Hannah Sell Yuba Raj Paudel Donald Voaklander Shannon E MacDonald Source Type: research
